Laser induced oxidation Raman spectroscopy as an analysis tool for iridium-based oxygen evolution catalysts.

The study of degradation behavior of electrocatalysts in an industrial context calls for rapid and efficient analysis methods. Optical methods like Raman spectroscopy fulfil these requirements and are thus predestined for this purpose. However, the iridium utilized in proton exchange membrane electrolysis (PEMEL) is Raman inactive in its metallic state.

Deep brain stimulation halts Parkinson's disease-related immune dysregulation in the brain and peripheral blood.

Immune dysregulation in the brain and periphery is thought to contribute to the detrimental neurodegeneration that occurs in Parkinson's disease (PD). Identifying mechanisms to reverse this dysregulation is key to developing disease-altering therapeutics for this currently incurable disease. Here we utilized the longitudinal data from the Parkinson's Progression Marker Initiative to demonstrate that circulating lymphocytes progressively decline in PD and can be used to predict future motor symptom progression.

[Social factors and entry to the waiting list for kidney transplantation].

Introduction: Kidney transplant continues to be the best treatment option for patients with end-stage chronic renal failure. The shortage of organs and long waiting times mean that many patients arrive at the transplant with a significant level of deterioration. The objective was to analyze the relationship between socioeconomic variables and knowledge about pre-emptive kidney transplant in the pre-transplant consultation.

Planning Split-Apheresis Designs for Demonstrating Comparability of Cellular and Gene Therapy Products.

A recent FDA draft guidance discusses statistical considerations for demonstrating comparability of cell and gene therapy products and processes. One experimental study described in the guidance is the split-apheresis design. The FDA draft guidance recommends a paired data analysis for such a design.

Quality of life and tolerability of B-cell directed therapy of multiple sclerosis with ofatumumab in a patient-centered real-world observational study.

Introduction: Ofatumumab (Kesimpta) is a subcutaneous CD20-targeting antibody approved in Germany in 2021 for the treatment of relapsing multiple sclerosis (RMS). After careful instruction, patients can administer the treatment themselves. We previously reported data of 101 patients (Klimas et al.